(Q78482942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

editorial

0 references

title

How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Stefan D Anker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Andrew J S Coats

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

language of work or name

English

0 references

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cardiology

14 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

123-130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1.

14 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Basic mechanisms in heart failure: the cytokine hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Recent insights into the role of tumor necrosis factor in the failing heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Plasma cytokine parameters and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Cytokines as emerging targets in the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Cytokines as new treatment targets in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Uric acid in chronic heart failure: a marker of chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

Heart Failure 99 -- the MOXCON story

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure--and an interaction with beta blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900470-9

7 January 2021

10.1016/S0167-5273(02)00470-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12419548%20AND%20SRC:MED&resulttype=core&format=json